Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sarepta Therapeutics Inc (SRPT), ISIS Pharmaceuticals, Inc. (ISIS): Is Questcor Pharmaceuticals Inc (QCOR) Still Undervalued?

In addition, Questcor Pharmaceuticals Inc (NASDAQ:QCOR) is active in adding more conditions to the label of the drug. Recently, the company started phase 2 trials for amyotrophic lateral sclerosis — a progressive, degenerative disease that significantly alters one’s quality of life. According to the ALS Association, the average life expectancy from the time of diagnosis for someone affected by this disorder is about two to five years. If the company is successful in adding this condition to the label; it will further enhance the portfolio of the company and provide future growth avenue.

The company recently announced its second-quarter results, which substantiates the optimism about the future growth of the business. Its recent quarter earnings per share increased by 96% amounting to $1.35 compared to the same time last year. Furthermore, vial shipments have gone up by 50% compared to the same quarter last year.

Other players working on orphan drugs
There are a number of companies working on orphan drug development — the orphan drug act was passed in 1983 to encourage companies to develop drugs for rare diseases that affect less than 200,000 Americans. Under the act, companies are offered tax credit, seven years marketing exclusivity and special pricing to cover the development costs.

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) recently received approval for its orphan drug, Kynamro — a drug to decrease the inherited cholesterol disorder. The drug is expected to get $136 million in sales in its first year. However, almost all of the proceeds will come from GlaxoSmithKline and Biogen Idec due to the marketing rights for the potential drugs. The stock has more than doubled since the approval of the drug, and the future prospects of the company look good. Recently, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) reported mid-stage data for its drug, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)-APOCIIIRx – the drug reduced bad cholesterol levels by 64% and increased good cholesterol levels by 52%.
Sarepta Therapeutics Inc (NASDAQ:SRPT) is working on eteplirsen, a drug to treat Duchenne muscular dystrophy, a rare disease that causes progressive loss of muscle function in young boys. There is a real need for the cure in the market and the drug will be categorized as an orphan drug, if approved. The company will charge between $150,000 and $200,000 for the drug. Sarepta Therapeutics Inc (NASDAQ:SRPT) will prove to be an extremely attractive long-term investment as there is no therapy available for the disease. Once the drug is approved, the company will be able to market the drug exclusively for seven years. As a result, there will be massive growth in revenues for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Summary
Questcor is still undervalued, in my opinion. I expect the growth to continue over the next three to five years. As a result, the stock will be trading substantially higher than the current levels. The only concern for Questcor is another regulatory probe into the dealings of the company. If the company is able to deal with this risk then I do not see any other pitfall for Questcor in the near future.

The article Is Questcor Still Undervalued? originally appeared on Fool.com is written by Ishtiaq Ahmed.

Ishtiaq Ahmed has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.